Cosmic voids look empty but they may be tearing the universe apart

Scientists at Oregon Health & Science University have developed a new molecule that could open the door to treating triple-negative breast cancer, one of the most aggressive and difficult-to-treat forms of the disease. The compound, called SU212, targets and disables a key enzyme that cancer cells rely on to fuel their growth. In tests using humanized mouse models, the molecule caused tumors to shrink and slowed the spread of cancer by forcing the enzyme to break down.